1. Vancomycin-induced ototoxicity in very-low-birthweight infants
- Author
-
Claudia Roll, Egbert Herting, Janina Marissen, Ingmar Fortmann, Joachim Eichhorn, Wolfgang Göpel, Christoph Härtel, Tanja K. Rausch, Jürgen Wintgens, Thomas Schaible, Friedhelm Heitmann, Alexander Humberg, Anja Stein, and Arne Simon
- Subjects
0301 basic medicine ,Microbiology (medical) ,Pediatrics ,medicine.medical_specialty ,030106 microbiology ,Medizin ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Ototoxicity ,Vancomycin ,030225 pediatrics ,medicine ,Birth Weight ,Humans ,Pharmacology (medical) ,Prospective Studies ,Prospective cohort study ,Pharmacology ,medicine.diagnostic_test ,Cumulative dose ,business.industry ,Infant, Newborn ,Infant ,medicine.disease ,Infectious Diseases ,Quartile ,Cohort ,Hearing test ,Audiometry ,business ,medicine.drug - Abstract
Background Vancomycin is an extensively used anti-infective drug in neonatal ICUs. However, exposure–toxicity relationships have not been clearly defined. Objectives To evaluate the risk profile for hearing deficits in vancomycin-exposed very-low-birthweight infants (VLBWI). Methods In a large cohort study of the German Neonatal Network (GNN; n = 16 967 VLBWI) we assessed the association of vancomycin treatment and pathological hearing tests at discharge and at 5 year follow-up. We performed audits on vancomycin exposure, drug levels, dose adjustments and exposure to other ototoxic drugs in a subgroup of 1042 vancomycin-treated VLBWI. Results In the GNN cohort, 28% (n = 4739) were exposed to IV vancomycin therapy. In multivariable logistic regression analysis, vancomycin exposure proved to be independently associated with pathological hearing test at discharge (OR 1.18, 95% CI 1.03–1.34, P = 0.016). Among vancomycin-treated infants, a cumulative vancomycin dose above the upper quartile (>314 mg/kg bodyweight) was associated with pathological hearing test at discharge (OR 2.1, 95% CI 1.21–3.64, P = 0.009), whereas a vancomycin cumulative dose below the upper quartile was associated with a reduced risk of pathological tone audiometry results at 5 years of age (OR 0.29, 95% CI 0.1–0.8, P = 0.02, n = 147). Conclusions Vancomycin exposure in VLBWI is associated with an increased, dose-dependent risk of pathological hearing test results at discharge and at 5 years of age. Prospective studies on long-term hearing impairment are needed.
- Published
- 2019